After the successful results of anti IL23 p40 and p19 monoclonal antibodies in reducing intestinal inflammation in Crohn’s Disease (CD) (70, 106) another form of IBD, targeting of the IL23/IL17 axis was thought to be a good strategy for both CD and UC. The gene discussed is IL17A; the disease is inflammatory bowel disease.